Lannett Co Inc (LCI) Receives $21.00 Average Target Price from Brokerages
Shares of Lannett Co Inc (NYSE:LCI) have earned an average rating of “Hold” from the nine research firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $21.00.
LCI has been the topic of several research analyst reports. ValuEngine downgraded Lannett Co from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Lannett Co in a research note on Thursday, June 8th. Zacks Investment Research raised shares of Lannett Co from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Deutsche Bank AG reissued a “hold” rating and set a $23.00 target price (up previously from $22.00) on shares of Lannett Co in a report on Monday, July 17th. Finally, BidaskClub cut shares of Lannett Co from a “buy” rating to a “hold” rating in a report on Monday, July 24th.
Hedge funds have recently modified their holdings of the business. State of Alaska Department of Revenue raised its holdings in Lannett Co by 77.6% during the 2nd quarter. State of Alaska Department of Revenue now owns 5,753 shares of the company’s stock valued at $117,000 after acquiring an additional 2,513 shares during the period. Mason Street Advisors LLC raised its holdings in Lannett Co by 7.5% during the 1st quarter. Mason Street Advisors LLC now owns 6,870 shares of the company’s stock valued at $154,000 after acquiring an additional 482 shares during the period. Municipal Employees Retirement System of Michigan raised its holdings in Lannett Co by 4.5% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 6,940 shares of the company’s stock valued at $142,000 after acquiring an additional 300 shares during the period. Airain ltd bought a new stake in Lannett Co during the 1st quarter valued at $205,000. Finally, BNP Paribas Arbitrage SA raised its holdings in Lannett Co by 49.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,235 shares of the company’s stock valued at $188,000 after acquiring an additional 3,061 shares during the period. 88.06% of the stock is currently owned by institutional investors and hedge funds.
Shares of Lannett Co (NYSE:LCI) traded up 0.58% during trading on Tuesday, hitting $17.25. The stock had a trading volume of 313,508 shares. The company’s 50 day moving average price is $17.21 and its 200 day moving average price is $20.57. Lannett Co has a 52 week low of $14.90 and a 52 week high of $33.53. The company’s market capitalization is $643.15 million.
Lannett Co (NYSE:LCI) last posted its quarterly earnings data on Wednesday, August 23rd. The company reported $0.40 EPS for the quarter, meeting the consensus estimate of $0.40. Lannett Co had a positive return on equity of 19.80% and a negative net margin of 0.09%. The business had revenue of $139.10 million for the quarter, compared to the consensus estimate of $139.01 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. Lannett Co’s revenue for the quarter was down 17.6% on a year-over-year basis. Analysts predict that Lannett Co will post $2.57 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/15/lannett-co-inc-lci-receives-21-00-average-target-price-from-brokerages.html.
About Lannett Co
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.